VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder Aug 15, 2019
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray Jul 23, 2019
VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview Jun 25, 2019
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine Jun 20, 2019
VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects May 30, 2019
VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression May 2, 2019
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 Apr 3, 2019
Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder Apr 1, 2019
